Design, synthesis, and structure-activity relationship of imidazolidin-2-one-1,3,5-triazine conjugates as Enterovirus 71 and Coxsackievirus A16 Inhibitor.

Wen-li Gao1*, Jing-xiu Li2

1Department of Pediatrics, The People’s Hospital of Anyang City, Anyang, Henan 455000, PR China
2Department of Intensive Care Unit, Zhengzhou Peoples Hospital, Zhengzhou 450003, PR China

Abstract

Aim: All microbes (e.g., bacteria, fungi, virus, and parasite) capable of infection have coupled with high levels of multidrug resistance (MDR) which leads to the significant morbidity and mortality. The present study deals with the development of novel imidazolidin-2-one-1,3,5-triazine conjugates via facile synthetic route.

Methods: The structure of the target derivatives were ascertained by using various spectroscopic analyses. These compounds were assessed for the determination of inhibitory activity against Enterovirus 71 and Coxsackievirus A16.

Result: The results of the investigation revealed that, entire set of target derivatives showed considerable inhibition against both the tested virus in plaque reduction inhibitory assay with no cytotoxicity.

Conclusion: All target derivatives were synthesized and showed considerable inhibition against both the tested virus along with no cytotoxicity.

Keywords: Synthesis, 1,3,5-triazine, imidazolidin-2-one, Enterovirus 71, Coxsackievirus A16.

Introduction

The rise of antimicrobial resistance to currently available therapeutic regimens for the treatment of infections has sternly affected the safety of public across the globe [1,2]. Almost all microbes (e.g., bacteria, fungi, virus, and parasite) capable of infection have coupled with high levels of multidrug resistance (MDR) which leads to the significant morbidity and mortality [3-5]. It frequently coupled with increased healthcare cost and prolonged hospital days [6]. Despite of better understanding of pathogenesis of infection, the rate of discovery of new drugs is declining more rapidly in contrast to rate at which microbes acquired resistance [7]. Therefore, this has put selective pressure on the discovery of new medicines and has less chance of resistance due to the presence structural diversity [8].

The hand, foot, and mouth disease (HFMD) is a common viral infection caused by Enterovirus belonging to the family Picornaviridae [9,10]. It majorly affects infants and children younger than 5 years old causing rashes, with rare instance of neurological disorder that can swiftly get worse to cardiopulmonary collapse [11]. According to recent estimates of WHO, China is severally affected by HFMD which is responsible for 431 deaths and 1,520,274 new infections up to end of July in 2012 [12]. Despite of advances in pathogenesis and etiology of the disease, no direct acting antiviral drugs are currently available to treat severe infection [13]. Therefore, the discovery of novel drug is urgently needed. Recently, Shia et al. has reported the discovery the pyridyl imidazolidinones as a novel class of enteroviral 71 inhibitor [14]. It acts via engaging the capsid protein. 1,3,5-triazine is also reported to exhibit number of pharmacological activity, such as, antibacterial [15], antimalarial [16], antidiabetic [17], CFTR inhibitor [18], carbonic anhydrase inhibitor [19] and antiviral agent [20].

Prompted by the above, the present manuscript deals with the development of novel conjugates of imidazolidin-2-one with 1,3,5-triazine as inhibitor of Enterovirus 71 and Coxsackievirus A16 to bring novel chemical diversity.

Materials and Methods

The chemical used in the present study was procured from Sigma Aldrich (USA). The spectra of 1H NMR and 13C NMR were recorded on Bruker Avance 400 and Bruker Avance 500 Spectrophotometer, respectively. The chemical shifts are expressed in parts per million (ppm), and coupling constants are expressed in Hertz (Hz). The Low-resolution mass spectrum (MS) was recorded on a Waters ZQ LC/MS single quadrupole system equipped with an electrospray ionization (ESI) source. The elemental analysis of the final derivatives was performed via Vario Elemental analyser. The Thin-layer
chromatography was performed on 0.25 mm Merck silica gel plates (60F-254) and visualized under UV light.

General procedure for the synthesis of 4,6-dichloro-1,3,5-triazin-2-amine. 2

The synthesis of mono-substituted 1,3,5-triazine was performed in accordance with earlier reported procedure. The solution of 2,4,6-tri chloro-1,3,5-triazine (1) (0.1 mol) in 25 mL acetone maintaining the temperature 0-5°C and strong ammonia solution (0.1 mol) was added constantly to above solution and stirred for 3 h followed by addition of NaHCO₃. The products was filtered and washed with cold water and recrystallized with ethanol to afford pure products [16].

General procedure for the synthesis of 6-chloro-N₂-(pyridin-4-yl)-1,3,5-triazin-2,4-diamine 3

4,6-dichloro-1,3,5-triazin-2-amine 2 (0.1 mol) was added into 50 mL of acetone maintaining temperature 40-45°C and pyridine-4-amidine solution (0.1 mol) was added constantly to above solution and stirred for 6 h followed by addition of NaHCO₃. The products was filtered and washed with cold water and recrystallized with ethanol to afford pure products [15].

General procedure for the synthesis of 6-substituted-N₂-(pyridin-4-yl)-1,3,5-triazin-2,4-diamine 4 (a-j)

6-chloro-N₂-(pyridin-4-yl)-1,3,5-triazin-2,4-diamine 3 (0.1 mol) was added in to 60 mL of 1,4 dioxane maintaining temperature 100-110°C. Different aromatic and aliphatic amine (a-j) (0.1 mol) solution were added constantly to above solution and reflux for 8-9 h followed by addition of K₂CO₃ (0.1 mol). The product was filtered and washed with cold water and recrystallized with ethanol to afford the corresponding pure product 4 (a-j).

General procedure for the synthesis of intermediate compounds 5 (a-j)

To stirring solution of 6-substituted-N₂-(pyridin-4-yl)-1,3,5-triazin-2,4-diamine 4 (a-j) (0.01 mol) in ethanol (25 mL) and 2-Chloroethyl isocyanate (0.01 mol) was added, the reaction mixture was stirred at room temperature for 1 to 3 days. The solvent was evaporated under reduced pressure, and the compound was purified by flash chromatography to give intermediate 5 (a-j) respectively.

General procedure for the synthesis of title compounds 6 (a-j)

To ice cold solution of intermediate 5 (a-j) (0.01 mol) in dry THF (30 mL) maintaining temperature 0-5°C and Sodium hydride (0.03 mol) was added to above solution, the reaction mixture was stirred at room temperature for 6 h. The solvent was evaporated under reduced pressure and aqueous phase was extracted thrice by methylene chloride (25 mL). The organic phases were washed with brine (30 mL), dried over anhydrous sodium sulphate and the compound was purified by flash chromatography to give title compounds 6 (a-j) respectively.

1-(4-((4-chlorophenyl)amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6a)

Yield: 79%; MP: 183-184°C; MW: 382.81; Rf: 0.68; FT-IR (νmax; cm⁻¹ KBr): 3389 (N-H str), 3071 (Ar -H str), 1712 (C=O str), 1628 (C=N str), 1104 (C-N str ), 712 (-C-Cl str) cm⁻¹; 1H-NMR (400MHz, DMSO, TMS) δ ppm: 8.47-7.02 (m, 4H, Pyridine), 7.67-7.21 (m, 4H, ArH), 6.02 (s, 1H, NH-imidazolidin-2-one), 3.96 (s, 2H, -NHX₂), 3.43-3.39 (m, 4H, imidazolidin-2-one); 13C-NMR (100 MHz, CDCl₃) δ ppm: 176.4, 168.8, 165.6, 158.7, 155.3, 150.3, 137.2, 129.7, 127.8, 122.3, 109.2, 28.8, 27.9; Mass : 382.87 (M+1); Elemental analysis for C₁₇H₁₃ClN₃O: Calculated: C, 53.34; H, 3.95; N, 29.27; Found: C, 53.37; H, 3.92; N, 29.31.

1-(4-((3-chlorophenyl)amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6b)

Yield: 71%; MP: 188-189°C; MW: 382.81; Rf: 0.63; FT-IR (νmax; cm⁻¹ KBr): 3384 (N-H str), 3075 (Ar -H str), 1706 (C=O str), 1624 (C≡N str), 1108 (C≡N str ), 718 (-C-Cl str) cm⁻¹; 1H-NMR (400MHz, DMSO, TMS) δ ppm: 8.46-7.04 (m, 4H, Pyridine), 7.52-6.81 (m, 4H, ArH), 6.04 (s, 1H, NH-imidazolidin-2-one), 3.98 (s, 2H, -NHX₂), 3.45-3.41 (m, 4H, imidazolidin-2-one); 13C-NMR (100 MHz, CDCl₃) δ ppm: 176.4, 168.6, 165.9, 158.3, 155.4, 150.5, 133.2, 130.7, 122.4, 116.9, 115.7, 109.2, 28.7, 27.8; Mass : 382.84 (M+1); Elemental analysis for C₁₇H₁₃ClN₃O: Calculated: C, 53.34; H, 3.95; N, 29.27; Found: C, 53.35; H, 3.98; N, 29.24.

1-(4-((2-chlorophenyl)amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6c)

Yield: 67%; MP: 193-194°C; MW: 382.81; Rf: 0.69; FT-IR (νmax; cm⁻¹ KBr): 3387 (N-H str), 3077 (Ar -H str), 1702 (C=O str), 1621 (C≡N str), 1104 (C≡N str ), 715 (-C-Cl str cm⁻¹); 1H-NMR (400MHz, DMSO, TMS) δ ppm: 8.48-7.01 (m, 4H, Pyridine), 8.21-6.78 (m, 4H, ArH), 6.01 (s, 1H, NH-imidazolidin-2-one), 3.94 (s, 2H, -NHX₂), 3.44-3.42 (m, 4H, imidazolidin-2-one); 13C-NMR (100 MHz, CDCl₃) δ ppm: 176.3, 168.8, 165.6, 158.5, 155.3, 150.2, 136.4, 130.9, 127.7, 125.4, 122.9, 122.1, 109.2, 28.7, 27.9; Mass : 382.78 (M+1); Elemental analysis for C₁₇H₁₃ClN₃O: Calculated: C, 53.34; H, 3.95; N, 29.27; Found: C, 53.31; H, 3.97; N, 29.29.

1-(4-((4-fluorophenyl)amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6d)

Yield: 83%; MP: 173-174°C; MW: 366.35; Rf: 0.72; FT-IR (νmax; cm⁻¹ KBr): 3393 (N-H str), 3081 (Ar -H str), 1709 (C=O str), 1624 (C≡N str), 1174 (C-F str), 1170 (C-N str ), 617 cm⁻¹; 1H-NMR (400MHz, DMSO, TMS) δ ppm: 8.47-6.97 (m, 4H, Pyridine), 7.43-7.32 (m, 4H, ArH), 6.04 (s, 1H, NH-imidazolidin-2-one), 3.98 (s, 2H, -NHX₂), 3.43-3.31 (m, 4H, imidazolidin-2-one); 13C-NMR (100 MHz, CDCl₃) δ ppm: 176.4, 168.8, 165.7, 158.9, 157.4, 155.4, 150.3, 134.6, 120.7;
Design, synthesis, and structure-activity relationship of imidazolidin-2-one-1,3,5-triazine conjugates as Enterovirus 71 and Coxsackievirus A16 Inhibitor

116.4, 109.2, 28.7, 27.9; Mass : 367.38 (M+1); Elemental analysis for C17H15FN8O: Calculated: C, 55.73; H, 4.13; N, 30.59; Found: C, 55.68; H, 4.09; N, 30.58.

1-(4-((3-fluorophenyl) amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6e)

Yield: 69%; MP: 179-180°C; MW: 366.35; Rf: 0.79; FT-IR (νmax; cm⁻¹ KBr): 3397 (N-H str), 3085 (Ar-C-H str), 1704 (C=O str), 1627 (C=N str), 1172 (C-F str), 1109 (C-N str ), 618 cm⁻¹; ¹H-NMR (400MHz, DMSO, TMS) δ ppm: 8.45-6.98 (m, 4H, Pyridine), 7.76-6.65 (m, 4H, ArH), 6.01 (s, 1H, NH-imidazolidin-2-one), 3.98 (s, 2H, -NHX₂), 3.46-3.43 (m, 4H, imidazolidin-2-one); ¹³C-NMR (100 MHz, CDCl₃) δ ppm: 176.5, 167.8, 165.3, 158.8, 155.4, 150.3, 142.1, 131.1, 113.5, 110.5, 109.2, 104.8, 28.7, 27.7; Mass : 367.31 (M+1); Elemental analysis for C₁₇H₁₅FN₈O: Calculated: C, 55.73; H, 4.13; N, 30.59; Found: C, 55.67; H, 4.15; N, 30.61.

1-(4-((2-fluorophenyl) amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6f)

Yield: 65%; MP: 228-229°C; MW: 427.26; Rf: 0.57; FT-IR (νmax; cm⁻¹ KBr): 3399 (N-H str), 3083 (Ar-C-H str), 1712 (C=O str), 1628 (C=N str), 1103 (C-N str ), 1099 (C-Br str), 735 cm⁻¹; ¹H-NMR (400MHz, DMSO, TMS) δ ppm: 8.47-6.99 (m, 4H, Pyridine), 7.55-6.52 (m, 4H, ArH), 6.04 (s, 1H, NH-imidazolidin-2-one), 3.96 (s, 2H, -NHX₂), 3.45-3.43 (m, 4H, imidazolidin-2-one); ¹³C-NMR (100 MHz, CDCl₃) δ ppm: 176.3, 168.8, 165.9, 158.7, 155.4, 150.3, 150.1, 132.4, 128.6, 126.2, 118.7, 117.4, 109.1, 28.7, 27.8; Mass : 428.29 (M+1); Elemental analysis for C₁₇H₁₅BrN₈O: Calculated: C, 47.79; H, 3.54; N, 26.23; Found: C, 47.78; H, 3.56; N, 26.26.

1-(4-((2-bromophenyl) amino)-6-(pyridin-4-ylamino)-1,3,5-triazin-2-yl)imidazolidin-2-one. (6i)

Yield: 85%; MP: 204-205°C; MW: 393.36; Rf: 0.84; FT-IR (νmax; cm⁻¹ KBr): 3395 (N-H str), 3087 (Ar-C-H str), 1718 (C=O str), 1625 (C=N str), 1528 (NO₂ str), 1108 (C-N str ), 728 cm⁻¹; ¹H-NMR (400MHz, DMSO, TMS) δ ppm: 8.45-6.98 (m, 4H, Pyridine), 8.02-6.92 (m, 4H, ArH), 6.02 (s, 1H, NH-imidazolidin-2-one), 3.97 (s, 2H, -NHX₂), 3.43-3.42 (m, 4H, imidazolidin-2-one); ¹³C-NMR (100 MHz, CDCl₃) δ ppm: 176.3, 168.8, 165.7, 158.8, 155.3, 150.2, 145.3, 137.8, 124.7, 119.3, 109.2, 28.7, 27.8; Mass : 394.38 (M+1); Elemental analysis for C₁₇H₁₃BrN₈O: Calculated: C, 51.95; H, 3.81; N, 32.08; Found: C, 51.95; H, 3.81; N, 32.08.

Cytotoxicity assay

The cytoxicity induced by compounds on LLC-PK1 cell line was determined using the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay. The cells were seeded in 96-well cell culture plates in a volume of 100 µL containing 5000 c/w for LLC-PK1 cells in the culture medium and grown for 24 h prior to dosage. The medium was then restored with a fresh medium containing compounds at diverse concentrations (40-0.05 µg/mL). After 2 and further
incubation of 24 h at 37°C, the medium was removed, the cells were washed with phosphate buffer solution (PBS, pH 7.4) and then 10 µL of MTT solution (5 mg/mL in PBS) were added to each well. Formazan crystals were dissolved in 100 µL of a sodium dodecylsulfate solution (10% of SDS in HCl 0.01 M) and mixed with the above mixture which was further incubated for 4h. After overnight incubation (12-14 h) the absorbance was measured at 595 nm with a Tecan Ultra Evolution microplate reader. The mean absorbance for each dose of compound was expressed as a percentage of the untreated control well absorbance.

Scheme 1. Reagents and conditions: R (a-j) various amines (i) Ammonia solution, Acetone, stirr 3 h at 0-5°C, NaHCO₃ (ii) pyridin-4-amine, Acetone, stirr 6h at 40-45 °C , NaHCO₃ (iii) R-H (a-j) various amines, 1,4 dioxane, Reflux at 100-110°C for 8-9 h, K₂CO₃ (iv) 2-Chloroethyl isocyanate, stirred at room temp for 1 to 3 days (v) Sodium hydride, dry THF, stir 6 h at room temp.
Results and Discussion

Chemistry
The desired compounds 2, 3, 4(a-j), 5(a-j) and 6(a-j) were synthesised by the protocols as shown in Scheme 1. In first step, synthesis of mono-substituted 1,3,5-triazines 2 was achieved by the nucleophilic substitution of Cl atom of the 2,4,6-trichloro-1,3,5-triazine (1) with excess amount of ammonia gas. Whereas, in the second step, synthesis of di-substituted 1,3,5-triazines (3) was accomplished by nucleophilic substitution of the Cl atom of mono-substituted 1,3,5-triazines (2) with pyridin-4-amine. Whereas, in the third step, synthesis of tri-substituted 1,3,5-triazines 4 (a-j) were accomplished by the nucleophilic substitution at Cl atom of di-substituted 1,3,5-triazine (3) with different amines (a-j) as shown in Scheme 1. In the fourth step, synthesis of intermediate compounds 5(a-j) was accomplished by the reaction of 2-chloroethyl isocyanate with tri-substituted 1,3,5-triazine 4a-j. Moreover, the fifth step corresponds to the synthesis of title compounds 6 (a-j) via cyclization of side chain of 1-(2-chloroethyl) urea at 1,3,5-triazine by addition of sodium hydride.

Biological activity
Enterovirus 71 (EV71) and Coxsackievirus A16 (COX A16) are two viruses belonging to the Picornaviridae family, deemed as the causative agents of Hand, foot and mouth disease (HFMD). It is a common infectious disease affecting mainly infants and children. As per World Health Organization (WHO), over two million cases were diagnosed in the year 2013, including Japan, Vietnam, Singapore and making China as top most affecting country with 1,855,457 cases [12]. Currently, there is no antiviral drug for the treatment this infection, thus, synthesized analogues were also tested for its inhibitory activity against EV71 and COX A16 shown in Table 1. In Plaque reduction inhibitory assay, target analogues showed diverse range of inhibition. Compound 6a showed considerable inhibition of infection with IC50 of 15.53 and 19.30 µM against EV71 and COX A16, respectively. The activity has been improved more than three fold in the case of compound 6b against EV17 with mild reduction against COX A16. The further drastic reduction in activity was observed in the case of compound 6d and 6e against both the tested virus. However, a substantial improvement in activity was reported by compound 6f and 6g, isomeric substitution of methyl group, on meta and ortho, respectively. Further loss in activity was reported by compounds having the hydroxyl group against EV71 and COX A16, except compound 6j which showed prominent inhibition among all the derivatives against EV71. It showed significant inhibition of infection against both the tested virus species. All synthesized derivatives showed no significant anti-viral activity as compared Ribavirin standard drug. No specific upsurge in activity was reported by the tested compounds, containing electron withdrawing substituent. It was indicated that, the inhibitory activity of the tested compounds does not follow any specific pattern of inhibition.

Table 1. Antiviral activity of target compounds 6 (a-j) against Enterovirus 71 (EV71) and Coxsackievirus A16.

<table>
<thead>
<tr>
<th>Compound</th>
<th>IC50 (µM), EV71</th>
<th>IC50 (µM), COX A16</th>
</tr>
</thead>
<tbody>
<tr>
<td>6a</td>
<td>15.53</td>
<td>19.30</td>
</tr>
<tr>
<td>6b</td>
<td>5.36</td>
<td>14.24</td>
</tr>
<tr>
<td>6c</td>
<td>9.21</td>
<td>11.35</td>
</tr>
<tr>
<td>6d</td>
<td>17.65</td>
<td>30.27</td>
</tr>
<tr>
<td>6e</td>
<td>11.34</td>
<td>19.03</td>
</tr>
<tr>
<td>6f</td>
<td>8.95</td>
<td>8.26</td>
</tr>
<tr>
<td>6g</td>
<td>2.23</td>
<td>6.36</td>
</tr>
<tr>
<td>6h</td>
<td>18.36</td>
<td>29.01</td>
</tr>
<tr>
<td>6i</td>
<td>16.28</td>
<td>27.34</td>
</tr>
<tr>
<td>6j</td>
<td>2.46</td>
<td>21.81</td>
</tr>
<tr>
<td>Ribavirin</td>
<td>256</td>
<td>369</td>
</tr>
</tbody>
</table>

Conclusion
In conclusion the present study deals with the development of novel imidazolidin-2-one-1,3,5-triazine conjugates as Enterovirus 71 and Coxsackievirus A16 Inhibitor. Thus it would be hard to define any structural-activity relation for these compounds against EV71 and COX A16.

Table 2. Cytotoxicity of compounds 6 (a-j) in LLC-PK1 cells.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Percentage of Cell Viability</th>
</tr>
</thead>
<tbody>
<tr>
<td>6a</td>
<td>98</td>
</tr>
<tr>
<td>6b</td>
<td>97</td>
</tr>
<tr>
<td>6c</td>
<td>97</td>
</tr>
<tr>
<td>6d</td>
<td>98</td>
</tr>
<tr>
<td>6e</td>
<td>94</td>
</tr>
<tr>
<td>6f</td>
<td>91</td>
</tr>
<tr>
<td>6g</td>
<td>97</td>
</tr>
<tr>
<td>6h</td>
<td>95</td>
</tr>
<tr>
<td>6i</td>
<td>93</td>
</tr>
<tr>
<td>6j</td>
<td>94</td>
</tr>
</tbody>
</table>

It is highly desirable for potent bioactive compound that it highly desirable that, it should not associated with toxicity. Thus, the entire derivatives were tested for toxicity against LLC-PK1 cells at the dose of 50 µg/mL at 12 h showed in Table 2. Results showed that, none of the tested derivative exhibit significant toxicity at the tested dose for required time.

Table 2. Cytotoxicity of compounds 6 (a-j) in LLC-PK1 cells.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Percentage of Cell Viability</th>
</tr>
</thead>
<tbody>
<tr>
<td>6a</td>
<td>98</td>
</tr>
<tr>
<td>6b</td>
<td>97</td>
</tr>
<tr>
<td>6c</td>
<td>97</td>
</tr>
<tr>
<td>6d</td>
<td>98</td>
</tr>
<tr>
<td>6e</td>
<td>94</td>
</tr>
<tr>
<td>6f</td>
<td>91</td>
</tr>
<tr>
<td>6g</td>
<td>97</td>
</tr>
<tr>
<td>6h</td>
<td>95</td>
</tr>
<tr>
<td>6i</td>
<td>93</td>
</tr>
<tr>
<td>6j</td>
<td>94</td>
</tr>
</tbody>
</table>
derivatives showed considerable inhibition against both the tested virus in plaque reduction inhibitory assay with no cytotoxicity.

References


*Correspondence to:
Wen-li Gao
Department of Pediatrics,
The People’s Hospital of Anyang City
No.18 Jiefang Road,
Anyang,
Henan45500
P.R. China